MS, University of Cincinnati, 2024, Medicine: Clinical and Translational Research
Background: Pulmonary hypertension (PH) frequently complicates the course of patients with left heart disease (PH-LHD), and it is associated with worse clinical outcomes. Mortality calculators for PH-LHD are lacking, and it is unclear whether any risk prediction tools originally derived from other forms of PH can accurately predict outcomes in patients with PH-LHD.
Methods: We retrospectively analyzed data from 161 patients with a diagnosis of PH-LHD referred to our pulmonary hypertension center from 2016 to 2022. We calculated the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL 2.0) risk score and categorized patients as low, intermediate, or high-risk. We assessed survival and risk discrimination at 1—and 3-yrs using Kaplan-Meier, Cox proportional hazards, and concordance index.
Results: At the first outpatient visit, 15% of patients were stratified as low-risk, 27% as intermediate, and 57% as high-risk. Cumulative 1-year survival rates were 100%, 94%, and 91% for low, intermediate, and high-risk strata, respectively. Cumulative 3-year survival rates were 96%, 89%, and 70% for low, intermediate, and high-risk strata, respectively. We found no difference in outcomes at 1 yr between risk groups. High-risk patients had a significantly higher risk of death at 3 years using REVEAL 2.0 (HR 5.32, p<0.001). However, REVEAL 2.0 accurately discriminated high-risk patients; the Cox proportional hazard ratio was not statistically different between patients classified as intermediate-risk compared to low-risk.
Conclusion: REVEAL 2.0 accurately predicted 3-year survival in PH-LHD patients with high-risk features. However, the survival rates in patients classified as intermediate-risk were not significant, suggesting inaccurate classification for this group of patients.
Committee: Patrick Ryan Ph.D. (Committee Chair); Roman Jandarov Ph.D. (Committee Member); Jean Elwing (Committee Member); Jennifer Cook M.D. (Committee Member); Jose Gomez Arroyo M.D. Ph (Committee Member)
Subjects: Surgery